Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, postponed its IPO on Thursday. It had filed to raise $20 million by offering 2.2 million shares at a price range of $8 to $10. The company previously filed to raise $40 million in October but postponed the deal.
The Wilmette, IL-based company was founded in 2014 and booked n/a in sales for the 12 months ended June 30, 2019. It had planned to list on the Nasdaq under the symbol MNPR. JonesTrading, Aegis Capital Corp. and Arcadia Securities were set to be the joint bookrunners on the deal.
The article Oncology biotech Monopar Therapeutics postpones $20 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.